Introduction
CML-CP, leukemia, CML, ’
LEUKEMIA, CML, CHRONIC MYELOID LEUKEMIA
Chronic myeloid leukemia (CML) accounts for ~15% of all new cases of leukemia [Each TKI has a specific safety profile with associated side effects that can ultimately affect adherence to therapy and health-related quality of life (HRQOL). Hence, patient-reported outcomes (PROs) are critical in precisely reporting and evaluating patients’ HRQOL, symptoms, and side effects and the drug tolerability of long-lasting, daily treatments [Asciminib, unlike existing ATP-competitive TKIs, allosterically inhibits BCR::ABL1 through Specifically Targeting the ABL Myristoyl Pocket (STAMP) [ASCEMBL (NCT03106779) is the first randomized controlled study comparing treatments for patients with CML-CP who were resistant or intolerant to at least two prior TKIs. Asciminib (40 mg BID) demonstrated superior efficacy compared with bosutinib (500 mg QD) to meet the primary study endpoint of major molecular response (MMR) at 24 weeks. MMR rate at week 24 was 25.5% on asciminib versus 13.2% on bosutinib; the absolute difference in MMR rates after adjusting for major cytogenetic response status at baseline was 12.2% (95% confidence interval [CI], 2.19%–22.30%) [refs. [Previously presented HRQOL data based on ASCEMBL 24-week analysis indicated that patients treated with asciminib showed improvement in treatment-related symptoms and HRQOL compared to baseline and relative to bosutinib [